Radient Pharmaceuticals Corporation (RPC), a US-based developer of in vitro diagnostic (IVD) cancer tests, has entered into a strategic partnership agreement with Perceptive Imagineering, to expand the commercialisation of Onko-Sure IVD cancer test in Latin America.
Under the terms of the agreement, Perceptive Imagineering will represent RPC and conduct product registration, marketing, sales and support for the licensing and distribution of Onko-Sure as a cancer screen in Central America, South America, Mexico and the Caribbean.
Beginning with Colombia, Perceptive will seek government approval and work with regional and government leaders to promote brand and product awareness for Onko-Sure as a general cancer screen. Perceptive will also develop an Onko-Sure branded website adapted for the Latin American culture.
Onko-Sure is a simple, non-invasive, patent-pending and regulatory-approved in vitro diagnostic test that enables physicians and their patients to effectively monitor and/or detect certain types of cancers by measuring the accumulation of specific breakdown products in the blood called Fibrin and Fibrinogen Degradation Products (FDP).
Onko-Sure is approved by the US FDA for the monitoring of colorectal cancer and by Health Canada as a lung cancer screen and cancer monitoring tool.
Nancy Alvarez, president of Perceptive Imagineering, said: “It is our belief that if RPC and Perceptive can offer a non-invasive test that has the potential of detecting cancer in early stages, then the general Colombian population will be more proactive in seeking medical treatment for the deadly disease of cancer. One of the largest issues in Colombia and throughout South America in general, is a lack of urgency in seeking medical attention for health conditions.
“With the ability of potentially detecting cancer in earlier stages with Onko-Sure we hope to make proactive cancer testing a more culturally accepted practice. Our focus is to launch a full cancer screening awareness campaign in partnership with Radient Pharmaceuticals.”
Douglas MacLellan, chairman and CEO of Radient Pharmaceuticals, said: “We have great confidence in Dr. Alvarez and her team’s ability to successfully market and sell Onko-Sure in Latin America. Perceptive’s knowledge and deep understanding of this market make them an ideally-suited partner for RPC.
“We continue to execute an aggressive worldwide commercialization plan for Onko-Sure and are working diligently to help governments and healthcare professionals battle the deadly disease of cancer.”